Head-to-head · WeighScore
Lean Meds vs OrderlyMeds
The verdict
Lean Meds takes it — 81.8/100 to 67/100.
Lean Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Lean Meds holds one price at every dose, names four dispensing pharmacies and its compounding class, and undercuts the field on both molecules.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Lean Meds | OrderlyMeds |
|---|---|---|
| WeighScore | 81.8/100 | 67/100 |
| Grade | B− | C |
| Site position | #32 | #192 |
| Semaglutide | $79/mo (one-month plan, flat at every dose) | $74/mo (starting dose, 2-mo starter plan, new patients only, compounded) |
| Tirzepatide | $109/mo (one-month plan, flat at every dose) | $299/mo (compounded) |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Site position #32 · B−
Strengths
- The price holds at every dose — stated as “same price, every dose” — so titration does not raise the bill
- $79 for semaglutide and $109 for tirzepatide on a one-month plan are at the low end of what this ranking records
- States its compounding class in the footer of every page: state-licensed 503A compounding pharmacies
- Names four dispensing pharmacies with addresses and phone numbers, and names the prescribing medical group
- A nutritionist and unlimited check-ins are included, and shipping is free
Where it loses points
- The $49 in the homepage hero is the twelve-month tier, not the month-to-month rate, and the same page carries a “price increases in” countdown with no dated deadline
- A homepage chip reads “no auto rebill” while the Terms describe automatic charging at recurring intervals until canceled
- An “eligible for insurance” chip sits against an FAQ calling the service self-pay and Terms barring reimbursement from any payor
- The refund page signs both “Leanmeds, Inc.” and “Leanmeds LLC”, chooses Florida law and then fixes venue in Fulton County, Georgia
- A satisfaction rating and a member count are published with no platform and no denominator
- No individual clinician or NPI is published — the medical group is named, its clinicians are not
Site position #192 · C
FDAWarning letter issued to OrderlyMeds LLC dba OrderlyMeds in June 2026. See the FDA warning-letter database.
Strengths
- The starter rate and the standing rate are both published, so the step-up is visible before signing up
- No membership fees and no hidden costs, stated as such
- The dose ladder is published: four weeks at 0.25 mg then four weeks at 0.5 mg
- Brand-name routes are priced openly, at retail
Where it loses points
- The $74 rate is a two-month starter plan billed as $149 up front, and it is open only to patients new to GLP-1 medication; the standing monthly rate is $149
- Tirzepatide has no equivalent standing discount — $299/mo is the ongoing rate
- Brand-name routes are priced at retail: Wegovy $1,839 and Zepbound $1,498
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
- FDA issued OrderlyMeds LLC dba OrderlyMeds a warning letter in June 2026; the letter is public in FDA's warning-letter database
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). CoreAge Rx advertises flat dose pricing for compounded injections, with no membership fee; its consultation-fee and refund deadlines deserve a close read before paying.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.